These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 32943072)

  • 1. Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications.
    Teng F; Li M; Yu J
    BMC Med; 2020 Sep; 18(1):275. PubMed ID: 32943072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer.
    Cousin F; Desir C; Ben Mustapha S; Mievis C; Coucke P; Hustinx R
    Radiother Oncol; 2021 Apr; 157():47-55. PubMed ID: 33453313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report.
    Ye X; Yang J; Stebbing J; Peng L
    BMC Pulm Med; 2022 Feb; 22(1):54. PubMed ID: 35123465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer.
    Lu X; Wang J; Zhang T; Zhou Z; Deng L; Wang X; Wang W; Liu W; Tang W; Wang Z; Wang J; Jiang W; Bi N; Wang L
    Front Immunol; 2022; 13():918787. PubMed ID: 35795657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.
    Sun Y; Shao C; Li S; Xu Y; Xu K; Zhang Y; Huang H; Wang M; Xu Z
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):299-304. PubMed ID: 32757454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.
    Wang X; Guo G; Guan H; Yu Y; Lu J; Yu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):87. PubMed ID: 30777100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis.
    Correale P; Saladino RE; Giannarelli D; Sergi A; Mazzei MA; Bianco G; Giannicola R; Iuliano E; Forte IM; Calandruccio ND; Falzea AC; Strangio A; Nardone V; Pastina P; Tini P; Luce A; Caraglia M; Caracciolo D; Mutti L; Tassone P; Pirtoli L; Giordano A; Tagliaferri P
    Cells; 2020 Aug; 9(9):. PubMed ID: 32854442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
    Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
    Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges.
    Meng X; Liu Y; Zhang J; Teng F; Xing L; Yu J
    Cancer Lett; 2017 Oct; 405():29-37. PubMed ID: 28688973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation Recall Pneumonitis Induced by Anti-PD-1 Blockade: A Case Report and Review of the Literature.
    Chen Y; Huang Z; Xing L; Meng X; Yu J
    Front Oncol; 2020; 10():561. PubMed ID: 32411597
    [No Abstract]   [Full Text] [Related]  

  • 15. Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism.
    Yin J; Wu Y; Yang X; Gan L; Xue J
    Front Immunol; 2022; 13():830631. PubMed ID: 35464480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.
    Baraibar I; Melero I; Ponz-Sarvise M; Castanon E
    Drug Saf; 2019 Feb; 42(2):281-294. PubMed ID: 30649742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation Recall Pneumonitis Induced by Sintilimab: A Case Report and Literature Review.
    Wang M; Xu S; Zhu H
    Front Immunol; 2022; 13():823767. PubMed ID: 35280981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
    Remon J; Chaput N; Planchard D
    Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Pneumonitis Rates and Severity in Patients With Lung Cancer Treated by Immunotherapy, Radiotherapy, and Immunoradiotherapy.
    Aiad M; Fresco K; Prenatt Z; Tahir A; Ramos-Feliciano K; Stoltzfus J; Harmouch F; Wilson M
    Cureus; 2022 Jun; 14(6):e25665. PubMed ID: 35677739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation recall pneumonitis from immune checkpoint inhibitors after extra pulmonary radiation.
    Kao LE; Stover D
    Respirol Case Rep; 2023 Oct; 11(10):e01223. PubMed ID: 37731586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.